Johnson & Johnson’s Covid-19 booster is 94% effective when given two months after the first dose in the United States, the company said on Tuesday, adding that the booster increases antibody levels four to six times more than one shot.
A booster dose of J&J given six months after the first shot appears to be potentially even more protective against Covid, the company said, generating twelve times higher antibodies four weeks after the booster, regardless of age.
When given as a booster, the vaccine remained well tolerated, with side effects generally consistent with those seen after the initial dose, according to J&J.
“We have now generated evidence that a booster further increases protection against COVID-19 and is expected to significantly extend the duration of protection,” Paul Stoffels, scientific director of J&J, said in a statement.
The new data, provided in a press release, helps J&J advocate with the Food and Drug Administration to authorize a recall of some 14.8 million Americans who have so far received the company’s single-dose vaccine. .
The Biden administration last month announced plans to roll out boosters for people who have received Moderna and Pfizer vaccines. On Friday, an FDA advisory committee unanimously recommended booster shots of Pfizer for people aged 65 and older and other vulnerable Americans. A final decision from the agency is expected overnight.
U.S. health officials have said they need more data on the J&J vaccine before they can recommend boosters of those injections.
The 94% effectiveness rate of the J&J recall is for the United States, the company said. Globally, a booster given about two months after the first dose is 75% effective against symptomatic infection, according to the company. It has also been shown to be 100% effective against serious and critical illnesses, he said.
The company also released data from a real-world study that found that a single dose of its vaccine offered strong, long-lasting protection against Covid-19-related hospitalizations, demonstrating 81% effectiveness after several months. .
The new single-dose data is important because it is “essential to prioritize protecting as many people as possible from hospitalization and death given the continued spread of COVID-19 and rapidly emerging variants. The company said.
“A single-injection COVID-19 vaccine that is easy to use, distribute and administer that provides strong and long-lasting protection is crucial to immunizing the world’s population,” said Stoffels.